Glioblastoma treatment focuses on extending survival and maintaining quality of life through a coordinated, multimodal approach. Current care combines maximal safe resection, radiotherapy, and temozolomide, with emerging options tailored to tumor biology and patient needs.
Rapid advances in molecular profiling and adjuvant strategies continue to refine how clinicians define and deliver glioblastoma treatment. Understanding standard options and experimental pathways helps patients and caregivers navigate complex decisions with greater confidence.
| Treatment Modality | Typical Timing | Primary Goal | Key Considerations |
|---|---|---|---|
| Maximal Safe Resection | At diagnosis, before radiation | Reduce tumor mass | Balance extent of resection with neurological function |
| Concurrent Radiotherapy | Post-resection, over 6 weeks | Control residual microscopic disease | Fractionated protocol with daily fractions |
| Temozolomide Chemotherapy | Concurrent and adjuvant cycles | Enhance radiation effect and delay recurrence | Dose intensity and MGMT promoter status influence outcomes |
| Tumor Treating Fields | After chemoradiation | Disrupt tumor cell division | Portable device used up to 18–24 hours/day |
Maximal Safe Surgical Resection
Neurosurgical removal of as much visible tumor as safely possible is the cornerstone of initial glioblastoma treatment. Extent of resection strongly correlates with progression-free survival and overall survival, provided that eloquent cortex and critical tracts are preserved.
Goals and Technique
Surgeons use neuronavigation, intraoperative imaging, and awake mapping to maximize resection while minimizing deficits. Even limited resections provide tissue for accurate diagnosis and molecular profiling essential for subsequent planning.
Impact on Outcomes
Evidence shows that near-total removal, when feasible, improves response to adjuvant therapy and may extend median survival compared with biopsy alone. However, the procedure must never compromise quality of life through new neurological impairment.
Radiotherapy Approach and Schedule
After recovery from surgery, definitive radiotherapy targets the tumor bed and surrounding margin to control microscopic infiltrating cells. Conventional fractionation remains standard, but variations are explored in select settings.
Conventional Fractionation
Standard practice delivers 2 Gray per fraction, five days per week, for approximately six weeks, totaling around 60 Gray. This schedule balances tumor control with tolerable toxicity to normal brain.
Hypofractionation and Specialized Patterns
In older or frail patients, shorter regimens may achieve symptom control with reduced burden. Ongoing trials test dose-fractionation combinations to optimize convenience without sacrificing local control.
Temozolomide Chemoryadiation and Adjuvant Strategy
Temozolomide is an oral alkylating agent integrated with radiotherapy and continued afterward to further suppress tumor progression. Its use depends on MGMT promoter methylation status, which predicts better response.
Concurrent Phase
During radiotherapy, low-dose temozolomide sensitizes tumor cells, enhancing the effectiveness of radiation. Dose interruptions may occur due to hematologic or hepatic toxicities requiring close monitoring.
Adjuvant Cycle Schedule
After a four-week break, patients typically cycle temozolomide for six months with alternating days each month. Adjuvant intensity and duration are adjusted for tolerance and MGMT status.
Tumor Treating Fields and Emerging Systemic Options
Tumor Treating Fields employ alternating electric fields to interfere with glioblastoma cell division and are a standard maintenance option after chemoradiation. They are used alongside or after temozolomide in many protocols.
Device-Based Treatment
Patients wear insulated arrays on the scalp connected to a portable generator, requiring consistent daily use for signal-mediated disruption of mitosis. Skin irritation and adherence challenges are common but manageable.
Integration with Systemic Therapy
Investigational combinations pair TTFields with targeted agents, immunotherapies, or novel chemistries to overcome resistance. Participation in trials may provide access to cutting-edge strategies beyond standard care.
FAQ
Reader questions
What does maximal safe resection involve and why does it matter for glioblastoma treatment?
Maximal safe resection removes as much visible tumor as possible while protecting critical brain functions. It improves survival and creates tissue samples for molecular profiling that guide subsequent therapy decisions.
How is radiotherapy scheduled after glioblastoma surgery and what role does temozolomide play?
Radiotherapy typically follows surgery over six weeks with daily fractions. Temozolomide is given concurrently and continued afterward in cycles, especially when MGMT is methylated, to delay recurrence.
When are tumor treating fields used in the treatment pathway for glioblastoma?
Tumor Treating Fields are usually started after completing chemoradiation and continued as maintenance therapy, often in combination with temozolomide to suppress residual disease.
How does MGMT promoter methylation affect treatment options and outcomes in glioblastoma?
MGMT methylation predicts better response to temozolomide and improved survival, influencing both concurrent chemoradiation duration and adjuvant chemotherapy strategies. Prioritize maximal safe resection to obtain tissue and reduce burden. Complete concurrent radiotherapy and temozolomide when tolerated. Use MGMT status to guide chemotherapy intensity and duration. Consider TTFields and clinical trials for maintenance and progressive disease.